Bafna Pharmaceuticals (NSE:BAFNAPH) PE Ratio (TTM): 47.09 (As of Jul. 02, 2026) — 38% Above Median


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
60 GF Score
Price ₹220.86
GF Value ₹90.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals PE Ratio (TTM)?

Bafna Pharmaceuticals NSE:BAFNAPH -2.00% 60 PE Ratio (TTM) is 47.09 as of Jul. 02, 2026, which is 38% above its 10-year median of 34.13. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹90.70 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 636 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 76.26% on this metric.

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-02), Bafna Pharmaceuticals's share price is ₹220.86. Bafna Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.69. Therefore, Bafna Pharmaceuticals's PE Ratio (TTM) for today is 47.09.


The historical rank and industry rank for Bafna Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:

NSE:BAFNAPH' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 0.6   Med: 34.13   Max: 759
Current: 44.44


During the past 13 years, the highest PE Ratio (TTM) of Bafna Pharmaceuticals was 759.00. The lowest was 0.60. And the median was 34.13.


NSE:BAFNAPH's PE Ratio (TTM) is ranked worse than
76.26% of 636 companies
in the Drug Manufacturers industry
Industry Median: 20.67 vs NSE:BAFNAPH: 44.44

Bafna Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was ₹1.16. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.69.

As of today (2026-07-02), Bafna Pharmaceuticals's share price is ₹220.86. Bafna Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.69. Therefore, Bafna Pharmaceuticals's PE Ratio without NRI for today is 47.09.

During the past 13 years, Bafna Pharmaceuticals's highest PE Ratio without NRI was 334.85. The lowest was 0.58. And the median was 28.20.

Bafna Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was ₹1.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.69.

During the past 12 months, Bafna Pharmaceuticals's average EPS without NRI Growth Rate was 75.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was -0.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.90% per year.

During the past 13 years, Bafna Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 14.70% per year. The lowest was -117.70% per year. And the median was -0.60% per year.

Bafna Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was ₹1.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.69.


Bafna Pharmaceuticals  (NSE:BAFNAPH) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Bafna Pharmaceuticals PE Ratio (TTM) Related Terms


Bafna Pharmaceuticals PE Ratio (TTM) Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals PE Ratio (TTM) Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.60 17.25 24.65 42.61 24.09

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.61 23.50 47.31 38.04 24.09

NSE:BAFNAPH vs ZTS, UTHR: PE Ratio (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals PE Ratio (TTM) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's PE Ratio (TTM) falls into.


NSE:BAFNAPH
60GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
PE Ratio (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Bafna Pharmaceuticals's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=220.86/4.690
=47.09

Bafna Pharmaceuticals's Share Price of today is ₹220.86.
Bafna Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.69.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio (TTM) →
What does a PE Ratio (TTM) of 47.09 mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a PE Ratio (TTM) of 47.09 as of Jul. 02, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Bafna Pharmaceuticals and its competitors. This is 38% above median its historical median of 34.13. Over the past decade, Bafna Pharmaceuticals' PE Ratio (TTM) has ranged from 0.60 to 759.00. According to the industry distribution chart, Bafna Pharmaceuticals ranks #485 out of 636 companies in the Drug Manufacturers industry, placing it in the top 76.3%.
Is Bafna Pharmaceuticals' PE Ratio (TTM) too high?
Bafna Pharmaceuticals' current PE Ratio (TTM) of 47.09 is 38% above median its 10-year median of 34.13. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 759.00. The Drug Manufacturers industry median PE Ratio (TTM) is 20.67. Bafna Pharmaceuticals' value of 47.09 is 127.8% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #485 out of 636 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' PE Ratio (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #485 out of 636 companies for PE Ratio (TTM). This places Bafna Pharmaceuticals in the lower half of its industry. The industry median PE Ratio (TTM) is 20.67. Bafna Pharmaceuticals' value of 47.09 is 127.8% above this benchmark. Historically, Bafna Pharmaceuticals' own PE Ratio (TTM) has ranged from 0.60 to 759.00 over the past decade. While the company's 10-year median is 34.13 vs. the industry median of 20.67, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 20.67, based on 636 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current PE Ratio (TTM) of 47.09 is 127.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 20.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current PE Ratio (TTM) is 47.09, which is 38% above median its own 10-year median of 34.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.70, compared to a current price of ₹220.86 — trading 143.5% above its estimated fair value. The current PE Ratio (TTM) is 47.09, which is 38% above median its 10-year median of 34.13 and 127.8% above the Drug Manufacturers industry median of 20.67. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current PE Ratio (TTM) is 47.09 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹220.86 is trading 143.5% above its estimated GF Value™ of ₹90.70. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • PE Ratio (TTM): 47.09 (38% above median its 10-year median of 34.13)
  • GF Value™: ₹90.70 vs. price of ₹220.86 (143.5% above fair value)
  • GF Score™: 60/100 with 8 warning signs
  • Industry Position: 127.8% above the Drug Manufacturers median (#485 of 636)

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score

Get the complete analysis for NSE:BAFNAPH

PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹220.86
Price
₹90.70
GF Value